HPN601 / Merck (MSD) - LARVOL DELTA

Merck Completes Acquisition of Harpoon Therapeutics, Inc. (Merck (MSD) Press Release) - "Merck...announced the completion of the acquisition of Harpoon Therapeutics, Inc...Harpoon’s common stock will no longer be publicly traded or listed on the Nasdaq Stock Market...Harpoon’s lead candidate, MK-6070 (formerly known as HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small cell lung cancer (SCLC) and neuroendocrine tumors...Additional pipeline candidates include HPN217, a T-cell engager targeting B-cell maturation antigen (BCMA), currently in Phase 1 clinical development for the treatment of patients with relapsed/refractory multiple myeloma, and several preclinical stage candidates, including HPN601...Merck is recording a non-tax deductible charge to R&D expense of approximately $650 million."

M&A • Multiple Myeloma • Neuroendocrine Tumor • Small Cell Lung Cancer • Solid Tumor

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline (Businesswire) - "Merck...and Harpoon Therapeutics, Inc...today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million...'We look forward to further evaluating HPN328 in innovative combinations with other pipeline candidates.'...Additional pipeline candidates include HPN217 targeting B-cell maturation antigen (BCMA), currently in Phase 1 clinical development for the treatment of patients with relapsed/refractory multiple myeloma, and several preclinical stage candidates, including HPN601, a conditionally activated targeting epithelial cell adhesion molecule (EpCAM) for the treatment of certain patients with EpCAM expressing tumors....The transaction is expected to close in the first half of 2024 and will be accounted for as an asset acquisition."

M&A • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Small Cell Lung Cancer • Solid Tumor

Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) - "HPN217 (BCMA) Phase 1/2 trial for relapsed, refractory multiple myeloma...Interim data expected by year end 2022....HPN601 (EpCAM)...IND preparation is advancing, however, due to a contract manufacturer-driven delay, Harpoon expects to submit the IND in the first half of 2023."

P1/2 data • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor

Harpoon Therapeutics Provides Pipeline Development Milestones for 2022 (GlobeNewswire) - "Anticipated 2022 Milestones...HPN328 – Continue dose escalation to determine RP2D by year-end 2022; HPN217 – Select the RP2D and initiate dose expansion cohort during the first half of 2022; HPN536 – Complete dose escalation by year-end 2022; HPN424 – Complete dose escalation during the second half of 2022; HPN601 – IND submission by year-end 2022"

IND • Trial status • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor

Harpoon Therapeutics Provides Pipeline Update for TriTAC Clinical Programs and T Cell Engager Platforms (GlobeNewswire) - P1/2, N=114; NCT04184050; Sponsor: Harpoon Therapeutics; P1/2, N=57; NCT04471727; Sponsor: Harpoon Therapeutics; "Harpoon Therapeutics...provided a pipeline update on its programs, including the interim data presented from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma (R/R MM) at the 63rd American Society for Hematology (ASH) Annual Meeting and Exposition....Encouraging clinical activity in higher dose cohorts including a 63% ORR and 88% DCR reported in the 2150 µg/week cohort with 8 disease evaluable patients with R/R MM, including one minimal residual disease (MRD) negative, stringent CR.By the end of 2022, an IND submission for HPN601 is expected as well as identification of a second IND candidate from the ProTriTAC platform.

IND • P1/2 data • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Small Cell Lung Cancer • Solid Tumor

Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021 (GlobeNewswire) - "ProTriTAC™ is a modular and robust T cell engager prodrug platform with therapeutic index expansion observed across multiple tumor targets...Abstract #: 933...Data presented today illustrate the consistency and the robustness of the ProTriTAC™ platform in vitro and in vivo as demonstrated by cell-based assays, pharmacokinetic studies in non-human primates, and therapeutic index assessments in tumor-bearing animals across multiple tumor targets. IND-enabling studies are currently underway for Harpoon’s first ProTriTAC™ program (HPN601)."

Preclinical • Oncology

Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) - "Harpoon Therapeutics, Inc...announced today the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share...the net proceeds of the offering, together with other available funds, to fund the continued clinical development of HPN424 in metastatic castration-resistant prostate cancer, HPN536 in ovarian cancer and other solid tumors, HPN217 in multiple myeloma, and HPN328 for the treatment of small cell lung cancer and other neuroendocrine tumors expressing Delta-like canonical Notch ligand 3; to advance the development of....HPN601..."

Commercial • Genito-urinary Cancer • Gynecologic Cancers • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Neuroendocrine Tumor • Oncology • Ovarian Cancer • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor

Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire) - "Additionally, we expect to advance our HPN424, HPN536, and HPN217 clinical programs in the fourth quarter and present preclinical data at SITC for our first ProTriTAC development program, HPN601, for the treatment of solid tumor malignancies.”"

Clinical • Preclinical • Oncology • Solid Tumor

[VIRTUAL] HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors (SITC 2020) - "For example, clinical testing of solitomab, an EpCAM-targeting T cell engager, resulted in severe dose-limiting toxicities, including elevated liver transaminases, hyperbilirubinemia, and diarrhea. Conclusions HPN601 is a conditionally active EpCAM-targeting T cell engager with a ten-fold improved therapeutic window compared to a constitutively active EpCAM-targeting T cell engager. An EpCAM-specific T cell engager with an improved safety profile could address unmet needs in many solid tumors and demonstrate the feasibility of using conditionally active T cell engagers to target more solid tumor antigens."

Clinical • Oncology • Solid Tumor • EPCAM • IFNG • IL10 • IL2 • IL6

[VIRTUAL] HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors (SITC 2020) - "For example, clinical testing of solitomab, an EpCAM-targeting T cell engager, resulted in severe dose-limiting toxicities, including elevated liver transaminases, hyperbilirubinemia, and diarrhea. Conclusions HPN601 is a conditionally active EpCAM-targeting T cell engager with a ten-fold improved therapeutic window compared to a constitutively active EpCAM-targeting T cell engager. An EpCAM-specific T cell engager with an improved safety profile could address unmet needs in many solid tumors and demonstrate the feasibility of using conditionally active T cell engagers to target more solid tumor antigens."

Clinical • Oncology • Solid Tumor • EPCAM • IFNG • IL10 • IL2 • IL6

Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC Program at 35th SITC Annual Meeting (GlobeNewswire) - “The oral presentation today highlighted the following data: The successful use of a humanized rodent tumor xenograft model to assess therapeutic index by simultaneously measuring efficacy and toxicity in the same tumor-bearing animal. A surrogate EpCAM ProTriTAC has a 10x improved therapeutic index compared to its corresponding constitutively active T cell engager control when measuring efficacy and toxicity in the same animal. Improved tolerability of HPN601 in non-human primates and more potent anti-tumor activity in a rodent tumor model over the corresponding constitutively active T cell engager control. Potent anti-tumor activity across multiple EpCAM-expressing tumor models, demonstrating the ability of HPN601 to be activated in multiple tumor types.”

Preclinical • Oncology

[VIRTURL] HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors (SITC 2020) - No abstract available

Clinical • Oncology • Solid Tumor • EPCAM

Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting (GlobeNewswire) - “Harpoon Therapeutics, Inc…announced today that the preclinical data on HPN601 for the treatment of solid tumors has been accepted for oral presentation at the 35th Society for Immunotherapy of Cancer (SITC) annual meeting. The virtual meeting takes place November 9-14, 2020. HPN601 targets the tumor antigen EpCAM and is based on Harpoon’s proprietary ProTriTAC™ T cell engager prodrug platform designed to enable the effective targeting of more broadly expressed tumor antigens.”

Preclinical • Oncology • Solid Tumor